The neurobiology of two distinct subtypes of neurodegenerative apraxia of speech: phenotypes of Alzheimer disease related 4-repeat tauopathies

PROJECT SUMMARY Progressive apraxia of speech (PAOS) is a devastating neurodegenerative syndrome that ultimately shortens lifespan and is most commonly due to an Alzheimer’s disease related disorders (ADRD) four-repeat tauopathy. Nine years ago, we described two distinct subtypes of PAOS: phonetic PAOS characterized predominantly by articulatory distortions and prosodic PAOS characterized predominantly by slow speech rate and abnormal prosody. In the 1st cycle we demonstrated that speech, language, and neurological features differ across PAOS subtypes which helped to validate these subtypes as being distinct. We performed cross-sectional analyses including voxel-based morphometry of structural MRI, diffusion tensor imaging and 18F- fluorodeoxyglucose PET (FDG-PET) and found evidence for greater cortical involvement in phonetic PAOS. Leveraging autopsy data, we also demonstrated that the PAOS subtypes are associated with specific 4-repeat tauopathies (phonetic with corticobasal degeneration and prosodic with PSP) and have neuronal loss in distinct cortico-striatal and pallido-nigro-luysial-cerebellar regions. However, there are still many gaps in knowledge. Little is known about progression, and whether longitudinal rates of clinical progression differ in PAOS subtypes, whether anatomic and metabolic rates differ and can be detected with advanced neuroimaging techniques, and whether genetic and histopathologic features of iron, Alzheimer disease neuropathologic changes or other co-pathologies play any role in PAOS subtypes. In the 2nd cycle we will proceed in new directions to address these knowledge gaps and limitations using data collected from 120 PAOS patients including 47 patients from the 1st cycle. In Aim 1, we will determine whether rates of decline in speech and other communication features, including acoustic characteristics derived from a novel rate modulation task, or time to the development of clinical outcomes, are associated with subtype. This aim will be critical to aid diagnosis and prognostication of disease progression. In Aim 2, we will determine whether advanced and novel neuroimaging techniques can detect regional longitudinal differences and whether imaging differences correlate with differences in clinical change over time, across PAOS subtypes. We will analyze structural MRI, FDG-PET and quantitative susceptibility mapping (QSM) to assess volume, metabolism, and iron deposition. This aim will improve understanding of how differential involvement of these regions relate to PAOS subtypes and provide specific neuroimaging biomarkers for diagnosis and disease tracking which is also important for clinical trials. In Aim 3, we will determine the relationship between tau- and Alzheimer disease related genetic risk alleles, regional iron burden, Alzheimer disease neuropathologic changes, and other co-pathologies, and PAOS subtype. Results from this aim will improve our understanding of the neurobiology of PAOS subtype. Achieving the aims of the 2nd cycle will have significant clinical relevance to every speech-language pathologist and neurologist who diagnose and care for patients with speech and language disorders.